Imaging and phase I study of 111In- and 90Y-labeled anti-Lewis(Y) monoclonal antibody B3

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 1720-1730

  Pai Scherf, Lee H ^a   Carrasquillo, Jorge A ^b   Paik, Chang ^b   Gansow, Otto ^a   Whatley, Millie ^b   Pearson, Deb ^a   Webber, Keith ^c   Hamilton, Michael ^a   Allegra, Carmen ^a   Brechbiel, Martin ^a   Willingham, Mark C ^d   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY IN 111; MONOCLONAL ANTIBODY Y 90;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; BONE MARROW BIOPSY; CANCER DIAGNOSIS; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; EPITHELIUM TUMOR; FEMALE; HUMAN; MALE; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TUMOR LOCALIZATION;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INDIUM RADIOISOTOPES; LEWIS BLOOD-GROUP SYSTEM; MALE; METABOLIC CLEARANCE RATE; MICE; MIDDLE AGED; NEOPLASMS; TISSUE DISTRIBUTION; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 17444453362     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Wilder, R. B., DeNardo, G. L., and DeNardo, S. J. Radioimmunotherapy: recent results and future directions. J. Clin. Oncol., 14: 1383-1400, 1996.
2. Carrasquillo, J. A. Radioimmunotherapy of leukemia and lymphoma. In: H. Wagner (ed.), Principles of Nuclear Medicine, 2nd ed., pp. 1117-1132. Philadelphia: W. B. Saunders, 1996.
3. Waldmann, T. A., White, J. D., Carrasquillo, J. A., Reynolds, J. C., Paik, C. H., Bansow, O. A., Brechbiel, M. W., Jaffe, E. S., Fleisher, T. A., and Goldman, C. K. Radioimmunotherapy of interleukin-2R α-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood, 86: 4063-4075, 1995.
4. 131I-B1 (anti-CD20) antibody therapy with autologous stem cells transplantation for relapsed B cell lymphomas. Lancet, 346: 336-340, 1995.
5. 131I-anti-B1 (anti-CD20) antibody. N. Engl. J. Med., 329: 459-465, 1993.
6. 67CU-2IT-BAT-Lym-1 and opportunities for improvement. In: D. M. Goldenberg (ed.), Cancer Therapy with Radiolabeled Antibodies, pp. 217-227. Boca Raton, FL: CRC Press, 1995.
7. 131I-CC49 in colorectal cancer. Cancer (Phila.), 73: 1057-1066, 1994.
8. Meredith, R. F., Bueschen, A. J., Khazaeli, M. B., Plott, W. E., Grizzle, W. E., Wheeler, R. H., Schlom, J., Russell, C. D., Liu, T., and Lobuglio, A. F. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J. Nucl. Med., 35: 1017-1022, 1994.
9. Begent, R. H., Ledermann, J. A., Green, A. J., Bagshawe, K. D., Riggs, S. J., Searle, F., Keep, P. A., Adam, T., Dale, R. G., and Glaser, M. G. Antibody distribution and dosimetry in patients receiving radiolabeled antibody therapy for colorectal cancer. Br. J. Cancer, 60: 406-412, 1989.
10. Fujimori, K., Covell, D. G., Fletcher, J. E., and Weinstein, J. N. A modeling analysis of monoclonal-antibody percolation through tumors: a binding-site barrier. J. Nucl. Med., 31: 1191-1198, 1990.
11. Zhu, H., Baxter, L. T., and Jain, R. K. Potential and limitations of radioimmuno-detection and radioimmunotherapy with monoclonal antibodies. J. Nucl. Med., 38: 731-741, 1997.
12. Mausner, L. F., and Srivastava, S. C. Selection of radionuclides for radioimmunotherapy. Med. Phys., 20: 503-509, 1993.
13. Pastan, I., Lovelace, E. T., Gallo, M. G., Rutherford, A. V., Magnani, J. L., and Willingham, M. C. Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. Cancer Res., 51: 3781-3787, 1991.
14. Pai, L. H., Wittes, R., Setser, A., Willingham, M. C., and Pastan, I. Treatment of advanced solid tumors with immunotoxin LMB-1: an anti-LewisY antibody linked to recombinant PE38. Nat. Med., 2: 350-353, 1996.
15. 111In-labeled B3 monoclonal antibody: biodistribution and imaging studies in nude mice bearing human epidermoid carcinoma xenografts. Cancer Res., 53: 2834-2839, 1993.
16. Camera, L., Kinuya, S., Garmestani, K., Brechbiel, M. W., Wu, C., Pai, L. H., McMurry, T. J., Gansow, O. A., Pastan, I., Paik, C. H., and Carrasquillo, J. A. Comparative biodistribution of indium- and yttriumlabeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA). Eur. J. Nucl. Med., 21: 640-646, 1994.
17. Camera, I., Kinuya, S., Garmestani, K., Brechbiel, M. W., Wu, C., Pai, L. H., McMurry, T. J., Gansow, O. A., Pastan, I., Paik, C. H., and Carrasquillo, J. A. Evaluation of the serum stability and in vivo biodistribution of CH-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J. Nucl. Med., 35: 882-889, 1994.
18. 125I-radiolabeled T101 anti-CD5 monoclonal antibody. Int. J. Radiat. Appl. Instrum. Part B, 17: 201-207, 1990.
19. Carrasquillo, J. A., Mulshine, J. L., Bunn, P. A., Jr., Reynolds, J. C., Foon, K. A., Schroff, R. W., Perentesis, P., Steis, R. H., Keenan, A. M., Horowitz, M., et al. Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma. J. Nucl. Med., 28: 281-287, 1987.
20. Chinol, M., and Hnatowich, D. J. Generator-produced yttrium-90 for radioimmunotherapy. J. Nucl. Med., 28: 1465-1470, 1987.
21. 90Y-labeled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry. Int. J. Cancer, 3 (Suppl.): 71-76, 1988.
22. Press, O. W., Shan, D., Howell-Clark, J., Eary, J.. Appelbaum, F. R., Matthews, D., King, D. J., Haines, A. M., Hamann, P., Hinman, L., Shochat, D., and Bernstein, I. D. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res., 56: 2123-2129, 1996.
23. Hnatowich, D. J., Snook, D., Rowlinson, G., Stewart, S., and Epenetos, A. A. Preparation and use of DTPA-coupled antitumor antibodies radiolabeled with yttrium-90. Targeted Diagn. Ther. Ser., 1: 353-374, 1988.
24. 90Y from cyclic and acyclic ligand-antibody conjugates. Int. J. Radiat. Appl. Instrum. Part B, 18: 469-476, 1991.
25. Maecke, H. R., Riesen, A., and Ritter, W. The molecular structure of indium-DTPA. J. Nucl. Med., 30: 1235-1239, 1989.
26. Cotton, F. A., and Wilkinson, G. Advanced Inorganic Chemistry, 5th ed. New York: John Wiley, 1988.
27. Gansow, O. A. Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates. Int. J. Radiat. Appl. Instrum. Part B, 18: 369-381, 1991.
28. Roselli, M., Schlom, J., Gansow, O. A., Raubitschek, A., Mirzadeh, S., Brechbiel, M. W., and Colcher, D. Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts. J. Nucl. Med., 30: 672-682, 1989.
29. 90Y 1B4M-DTPA labeled anti-Tac monoclonal antibody. J. Nucl. Med., 40: 267-276, 1999.
30. DeNardo, S. J., Kramer, E. L., O'Donnell, R. T., Richman, C. M., Salako, Q. A., Shen, S., Noz, M., Glenn, S. D., Ceriani, R. L., and De Nardo, G. L. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a Phase I clinical trial. J. Nucl. Med., 38: 1180-1185, 1997.
31. Knox, S. J., Goris, M. L., Trisler, K., Negrin, R., Davis, T., Liles, T. M., Grillo-Lopez, A., Chinn, P., Varns, C., Ning, S. C., Fowler, S., Deb, N., Becher, M., Marquez, C., and Levy, R. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin. Cancer Res., 2: 457-470, 1996.
32. Wiseman, G. A., Solinger, A. M., and Grillo-Lopez, A. IDEC-Y2B8 (Y-90 conjugated anti-CD20) dosimetry calculated from In-111 anti-CD20 in patients with low and intermediate grade B-cell non-Hodgkin's lymphoma (NHL) emphasis on bone marrow (BM). Blood, 90 (Suppl.); 2273-2273, 1997.
33. Lindmo, T., Boven, E., Cuttitta, F., Fedorko, J., and Bunn, P. A., Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods, 72: 77-89, 1984.
34. Recommended methods for measurement of red-cell and plasma volume: International Committee for Standardization in Haematology. J. Nucl. Med., 21: 793-800, 1980.
35. Gibaldi, M. Biopharmaceutics and Clinical Pharmacokinetics, 3rd ed. Philadelphia: Lea & Febiger, 1984.
36. Loevinger, R., and Berman, M. Calculating the absorbed dose from biologically distributed radionuclides. MIRD Pamphlet #1. New York: The Society of Nuclear Medicine, 1976.
37. Ellis, R. E. The distribution of active bone marrow in the adult. Phys. Med. Biol., 5: 255-258, 1961.
38. Sgouros, G., Jureidini, I. M., Scott, A. M., Graham, M. C., Larson, S. M., and Scheinberg, D. A. Bone marrow dosimetry: regional variability of marrow-localizing antibody. J. Nucl. Med., 37: 695-698, 1996.
39. Reynolds, J. C., Del Vecchio, S., Sakahara, H., Lora, M. E., Carrasquillo, J. A., Neumann, R. D., and Larson, S. M. Anti-murine antibody response to mouse monoclonal antibodies: clinical findings and implications. Int. J. Radiat. Appl. Instrum. Part B, 16: 121-125, 1989.
40. Lloyd, K. O., and Old, L. J. Human monoclonal antibodies to glycolipids and other carbohydrate antigens: dissection of the humoral immune response in cancer patients. Cancer Res., 49: 3445-3451, 1989.
41. Tolcher, A. W., Sugarman, S., Gelmon, K. A., Cohen, R., Saleh, M., Isaacs, C., Young, L., Healey, D., Onetto, N., and Slichenmyer, W. Randomized Phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J. Clin. Oncol., 17: 478-484, 1999.
42. Abdel-Nabi, H. H., Schwartz, A. N., Higgano, C. S., Wechter, D. G., and Unger, M. W. Colorectal carcinoma: detection with In-111 anti-carcinoembryonic-antigen monoclonal antibody ZCE-025. Radiology, 164: 617-621, 1987.
43. Patt, Y. Z., Lamki, L. M., Haynie, T. P., Unger, M. W., Rosenblum, M. G., Shirkhoda, A., and Murray, J. L. Improved tumor localization with increasing dose of indium- 111 -labeled anti-carcinoembryonic antigen monoclonal antibody ZCE-025 in metastatic colorectal cancer. J. Clin. Oncol., 6: 1220-1230, 1988.
44. Welt, S., Divgi, C. R., Real, F. X., Yeh, S. D., Garin-Chesa, P., Finstad, C. L., Sakamoto, J., Cohen, A., Sigurdson, E. R., and Kemeny, N. Quantitative analysis of antibody localization in human metastatic colon cancer: a Phase I study of monoclonal antibody A33. J. Clin. Oncol., 8: 1894-1906, 1990.
45. Vriesendorp, H. M., Herpst, J. M., Germack, M. A., Klein, J. L., Leichner, P. K., Loudenslager, D. M., and Order, S. E. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01. J. Clin. Oncol., 9: 918-928, 1991.
46. Deb, N., Goris, M., Trisler, K., Saal, J., Ning, S., Becker, M., Marquez, C., and Knox, S. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin. Cancer Res., 2: 1289-1297, 1996.
47. Leichner, P. K., Alabani, G., Colcher, D., Harrison, K. A., Hawkins, W. G., Eckblade, M., Baranowska-Kortylewicz, J., Augustine, S. C., Wisecarver, J., and Tempero, M. A. Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49. J. Nucl. Med., 38: 512-516, 1997.
48. 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Clin. Cancer Res., 4: 2691-2700, 1998.
49. 90Y Mx-diethylenetriamine-pentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a Phase I trial. Cancer Res., 55 (Suppl.): 5921s-5924s, 1995.
50. White, C. A., Halpern, S. E., Parker, B. A., Miller, R. A., Hupf, H. B., Shawler, D. L., Collins, H. A., and Royston, I. Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies. Blood, 87: 3640-3649, 1996.
51. 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a Phase I radioimmunotherapy trial. Cancer Res., 55 (Suppl.): 5929s-5934s, 1995.
52. Leichner, P. K., Akabani, G., Colcher, D., Harrison, K. A., Hawkins, W. G., Eckblade, M., Baranowski-Kortylewicz, J., Augustine, S. C., Wisecarver, J., and Tempero, M. A. Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49. J. Nucl. Med., 38: 512-516, 1997.
53. Halpern, S. E., Haindl, W., Beauregard, J., Hagan, P., Clutter, M., Amox, D., Merchant, B., Unger, M., Mongovi, C., and Bartholomew, R. Scintigraphy with In-111-labeled monoclonal antitumor antibodies: kinetics, biodistribution and tumor detection. Radiology, 168: 529-536, 1988.
54. Press, O. W., Eary, J. F., Appelbaum, F. R., and Bernstein, I. D. Myeloablative radiolabeled antibody therapy with autologous bone marrow transplantation for relapsed B cell lymphomas. Cancer Treat. Res., 76: 281-297, 1995.
55. 131I-labeled chimeric antibody with peripheral blood progenitor cell transfusions. Cancer Res., 55 (Suppl.): 5916s-5920, 1995.
56. Stewart, J. S. W., Hird, V., Snook, D., Dhokia, B., Sivolapenko, G., Hooker, G., Papadimitriou, J. T., Rowlinson, G., Sullivan, M., Lambert, H. E., et al. Intraperitoneal yttrium-90 labeled monoclonal antibody in ovarian cancer. J. Clin. Oncol., 8: 1941-1950, 1990.